The therapeutic benefits of interferon-beta are limited, as some patients with multiple sclerosis (MS) do not respond to therapy. Based on their biological characteristics, non-responsive patients can be divided into three subgroups: genetic, pharmacological and pathogenetic non-responders. In order to tailor the best treatment in both newly diagnosed MS patients and those already receiving treatment, the neurologist must carefully consider the risk of treating non-responders. © Springer-Verlag Italia 2008.
CITATION STYLE
Bertolotto, A., & Gilli, F. (2008). Interferon-beta responders and non-responders. A biological approach. Neurological Sciences, 29(SUPPL. 2). https://doi.org/10.1007/s10072-008-0941-2
Mendeley helps you to discover research relevant for your work.